| Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. | |
| | |
MedLine Citation:
|
PMID: 11673814 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To compare in a real clinical setting the largely unknown midterm clinical effectiveness of two protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) regimens with different potency and tolerability profiles in naïve patients. METHOD: This study was a multicenter, open-label, randomized trial in naïve patients with less than 400 CD4+ cell count/microL, regardless of viral load. Treatment arms were hard gel capsule saquinavir (HGC-SQV)-based HAART (Arm A), with an expected more favorable tolerability profile, and indinavir (IDV)-based HAART (Arm B), with more potent virologic activity. While viro-immunological surrogate markers and World Health Organization (WHO) grade III toxicity (secondary endpoints) were regularly monitored, primary endpoints of the study were clinical and defined as any AIDS-defining event, AIDS-related death, WHO grade IV toxicity, drop outs, and protocol violations. RESULTS: 262 consecutive patients were enrolled in the study from March 1, 1997 to December 31, 1997, in 24 different Italian clinical centers (132, Arm A; 130, Arm B). After 24 months of follow-up, patients who were enrolled in Arm B showed a significantly higher rate of virological success (75% had viremia below 500 copies/mL, CI = 12.9%, in the on-treatment analysis) and immunological gain (mean CD4+ cell count increase of 274 CD4+ cells/microL, SD = 234) when compared to patients enrolled in arm A (57%, CI = 15.5% and 223 CD4+ cells/microL, SD = 192; p =.0353 and.026, respectively). Despite the significant difference observed in surrogate markers, the number of total primary endpoints did not differ in the two groups (55 out of 132 in Arm A vs. 58 out of 130 person-years in Arm B; p =.86). CONCLUSION: Our results suggest that, after 24 months of follow-up in a real clinical setting, a PI-based HAART induces significant clinical benefits in naïve patients even in the absence of a complete suppression of viral replication. However, the long-term clinical impact of the possible accumulation of viral mutations in the presence of low-grade viral replication remains to be elucidated. |
| | |
Authors:
|
G Carosi; F Castelli; F Suter; F Maggiolo; A M Orani; A Pan; M Andreoni; G M Vigevani; R Maserati; F Mazzotta; C Tinelli; |
Related Documents
:
|
3789694 - Interferon in the prevention of genital herpes recurrence. 19578244 - Clinical and virological responses to clevudine therapy in chronic hepatitis b patients... 9129064 - Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalci... 19640664 - Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatit... 3588844 - Late effects in the mouse small intestine after a clinically relevant multifractionated... 8210234 - Treatment of guillain-barré syndrome with high-dose immune globulins combined with met... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: HIV clinical trials Volume: 2 ISSN: 1528-4336 ISO Abbreviation: HIV Clin Trials Publication Date: 2001 Sep-Oct |
Date Detail:
|
Created Date: 2001-10-23 Completed Date: 2001-12-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100936377 Medline TA: HIV Clin Trials Country: United States |
Other Details:
|
Languages: eng Pagination: 399-407 Citation Subset: IM |
Affiliation:
|
Institute of Infectious and Tropical Diseases, University of Brescia, Italy. castelli@master.cci.unibs.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-HIV Agents / therapeutic use* Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Cohort Studies Female HIV Infections / drug therapy*, immunology, virology HIV Protease Inhibitors / therapeutic use* Humans Indinavir / therapeutic use Italy Male Prospective Studies Saquinavir / therapeutic use Viral Load |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/HIV Protease Inhibitors; 127779-20-8/Saquinavir; 150378-17-9/Indinavir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
Next Document: Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly proteas...